HIGHLIGHTS
- who: Pedro A. Lazo from the (CSIC), Universidad Salamanca, Salamanca, Spain have published the research: Targeting Histone Epigenetic Modifications and DNA Damage Responses in Synthetic Lethality Strategies in Cancer?, in the Journal: Cancers 2022, 14, x FOR PEER REVIEW of /2022/
- future: Another promising inhibitor berzosertib (VX-970 M6620) has been tested in non-small cell lung cancer (NSCLC) patients in combination with gemcitabine showing good tolerance in phase 2 trial indicating that further studies are necessary .
SUMMARY
In this context, drugs that alter chromatin dynamics or impair DNA repair pathways . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.